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The trail of my studies on glycoproteins
from enterokinase to tumor markers
By Ikuo YAMASHINA*1,†
(Communicated by Takao SEKIYA, M.J.A.)
Abstract: This review describes the results of the author’s studies on glycoproteins which
have been carried out for more than 50 years. Starting from the elucidation of basic structures of
glycoproteins, i.e. the structure of the linkage between an amino acid and a sugar and the occurrence
of the --mannosidic linkage as the common structure of glycoproteins, the author became interested
in the cell membrane glycoproteins focused on the comparison of cancer cells versus normal cells.
These studies were then extended to the establishment of sugar-directed and cancer-associated
monoclonal antibodies. Some of the monoclonal antibodies are useful for cancer diagnosis.
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Introduction
Glycoproteins are widely distributed in living
organisms and show considerable diversity in struc-
ture and function. I have been involved in the study
of the structures and biological functions of glyco-
proteins since 1953, and feel privileged to be able to
review the results of my studies, thanks to many
colleagues. This review comprises three sections.
Section I describes the basic structure of glycopro-
teins, i.e. the structure of the linkage between an
amino acid and a sugar. As to sugars, the occurrence
of the --mannosidic linkage was discovered as the
common structure of glycoproteins. Section II
describes the characterization of cell membrane
glycoproteins, and Section III describes sugar-di-
rected and cancer-associated monoclonal antibodies.
Section I. The basic structures of glycoproteins
(i) Isolation of a glycopeptide from ovalbu-
min. During the period of 1953 to 1957, I had the
chance to study at Karolinska Institutet in Stock-
holm, Sweden. Professor Eric Jorpes suggested that I
study “enterokinase”, which had been reported by a
Russian physiologist, I.V.Pavrov, to be present in the
duodenal contents, activating proteases secreted
from the pancreas. Trypsinogen was supposed to be
the substrate of enterokinase, but its function and
chemical entity were entirely unknown. After labo-
rious attempts to purify the enzyme, I ﬁnally
obtained a nearly homogeneous enterokinase prepa-
ration. The mechanism underlying the activation of
trypsinogen by enterokinase was revealed and this
discovery is now cited in all textbooks on biochem-
istry. However, I was more interested in the ﬁnding
that the sugar content of the enterokinase prepara-
tion amounted to 45%. There was no terminology for
glycoproteins at that time. Such preparations were
designated as mucoproteins or sugar–protein com-
plexes. I had a feeling that the polypeptide moiety
should be covalently linked to the sugar moiety, an
intuition based on the puriﬁcation procedures for
enterokinase.
After looking for glycoproteins that are easier to
prepare than enterokinase, I decided to use ovalbu-
min since this protein is easy to prepare on a large
scale and had been shown by Prof. Neuberger to
contain a few percent of sugar. The term “glyco-
proteins” was accepted universally when a book
entitled “Glycoproteins”, edited by Dr. Gottschalk,
was published in 1972.1)
An advantage that I had at that time was that
pronase, a potent proteinase with a broad speciﬁcity,
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min was digested extensively and ﬁnally a glycopep-
tide fraction was obtained that contained only
asparatic acid as an amino acid and additionally
ammonia in an equimolar amount, as judged after
hydrolysis. The sugar components were identiﬁed as
N-acetylglucosamine and mannose.2) This was no
longer glycopeptide, but it should be called glycosyl
asparagine (or aspartic acid). The glycopeptide was
then dinitrophenylated and subjected to partial
acid hydrolysis (2M HCl, 100°C, 20min.). The
hydrolysate contained several fragments that could
be separated by paper electrophoresis. One of the
fragments was composed of DNP-aspartic acid,
ammonia and glucosamine in an equimolar ratio.
This information prompted the Neuberger’s group to
synthesize aspartylglycosylamine (shown in Fig. 1).
The British group had previously synthesized the
aspartylglucosylamine (glucosamine being replaced
by glucose), and found that the acid hydrolysis rates
were nearly the same for the synthetic and natural
linkages between asparagine and the sugar compo-
nent. I also synthesized aspartylglycosylamine and
tried to conﬁrm the identity of the synthetic and
natural aspartylglycosylamines. In this experiment,
however, the yield of aspartylglycosylamine from
the natural glycosyl asparagine through partial acid
hydrolysis was only about 20% of the theoretical
value although the identity was unanimously proved
through the use of chromatographic techniques and
infra-red spectroscopy.3) The unequivocal conﬁrma-
tion of the linkage was obtained after the discovery of
an enzyme that is speciﬁc to this linkage.
(ii) Discovery of an enzyme hydrolyzing the
linkage between asparagine and N-acetylglucos-
amine. Aspartylglycosylamine is apparently a
derivative of asparagine in which one of the amide
hydrogens is substituted by N-acetylglucosamine.
This analogy would suggest that asparaginase may
be able to hydrolyze the amide linkage in asparatyl-
glycosylamine. Asparaginase from any source is
known to be useful for the clinical treatment of
leukemia patients since the leukemia viruses require
asparagine for their growth. In the animal kingdom,
asparaginase was known to be most abundant in
guinea pig serum. Some amount of guinea pig sera
was fractionated on an ion exchange column, and the
non-identity of asparaginase and the new enzyme was
clearly shown. The new enzyme was named “aspartyl-
glycosylamine amide hydrolase”, and its mode of
action, substrate speciﬁcity and subcellular distribu-
tion were examined.
As shown in Fig. 1, the enzyme, simply des-
ignated as amidase, hydrolyzes the amide linkage
producing aspartic acid and glycosylamine (1-amino-
N-acetylglucosamine). Glycosylamine was slowly
hydrolyzed non-enzymatically to produce ammonia
and N-acetylglucosamine. This non-enzymatic reac-
tion proceeded at a higher rate as the pH value fell.4)
Large scale puriﬁcation of the enzyme was carried
out from hog liver, which was found to contain a
relatively large amount of the enzyme, a homoge-
neous preparation being obtained. It became clear
that a single enzyme is involved in the cleavage of
aspartylglycosylamine, verifying the reaction mecha-
nism shown in Fig. 1.5)
Quantitative isolation of aspartylglycosylamine
from glycosyl asparagine was attempted using both
chemical and enzymatic methods. The chemical
method used was Smith degradation. Peeling oﬀ of
the mannose and N-acetylglucosamine residues by
repeating the procedures, comprising oxidation with
periodate, reduction and mild acid hydrolysis, led to
the isolation of aspartylglycosylamine nearly quanti-
tatively. For enzymatic methods, ,-mannosidase, --
mannosidase and --N-acetylglucosaminidase were
used, which also led to the isolation of aspartyl-
glycosylamine quantitatively. Of the glycosidases we
used, --mannosidase was newly prepared from a snail
(Achatina fulica), and it enabled us to discover the
CH2OH
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-
Fig. 1. Enzymatic cleavage of aspartylglycosylamine.
The trail of my studies on glycoproteins from enterokinase to tumor markers No. 6] 579occurrence of the --form of the innermost mannose
residue in the sugar moiety of ovalbumin.6) The --
form mannose residue was then ubiquitously detected
in all the glycoproteins so far investigated.
Several aspartylglycosylamines have been syn-
thesized in which natural N-acetylglucosamine was
replaced by mannose, galactose, and N-acetylgalacto-
samine, respectively. These synthetic aspartyl-
glycosylamines were hydrolyzed with puriﬁed ami-
dase at rates that are not very diﬀerent from that
with the natural aspartylglycosylamine.7) However,
these new types of linkage between asparagine and
sugars other than N-acetylglucosamine have not been
detected in any glycoproteins so far.
Amidase seems to require the free ,-amino and
,-carboxyl groups of asparagine for its activity, but
exhibits a broad speciﬁcity as regards the sugar
moiety. Monosaccharides and even oligosaccharides
are utilized. Amidase splits oﬀ aspartic acid from
the glycosyl asparagine from ovalbumin and some
glycosyl asparagine from serum glycoproteins (e.g.
orosomucoid). Thus, amidase provides decisive evi-
dence for the aspartylglycosylamine linkage in
glycoproteins. Amidase is, however, not useful for
the release of the sugar moiety from the polypeptide
moiety in native glycoproteins. Recently, a new
enzyme named N-glycanase has become available
for release of the sugar moieties from undigested
polypeptide moieties.8)
Amidase was found to be a lysosomal enzyme,9)
which suggested the possibility of a new genetic
disease caused by a deﬁciency of this enzyme. In fact,
the ﬁrst report of this possibility appeared in the UK,
and then hundreds of patients with this disease were
found in Finland.10) The disease was named “aspar-
tylglycosylaminuria” and characterized by the daily
excretion of about 300mg of aspartylglycosylamine in
the urine. Some of the aspartylglycosylamine pos-
sessed one or two moles of mannose attached to --N-
acetylglucosamine, probably due to the addition of a
mannose residue during excretion.11)
(iii) Classiﬁcation of glycoproteins. Glyco-
proteins are divided into two groups based on the
nature of the sugars and their modes of linkage to
proteins. One group is referred to as serum-type
glycoproteins, which consist predominantly of man-
nose-containing sugar chains linked N-glycosidically
via N-acetylglucosamine to asparagine in the poly-
peptide. The other group is referred to as mucin-type
glycoproteins, which consist predominantly of man-
nose-free sugar units O-glycosidically linked via N-
acetylgalactosamine to serine and/or threonine in the
polypeptide.12) These two groups of glycoproteins can
be distinguished further based on structural charac-
teristics. In mucin-type glycoproteins, the sugar units
(chains) are densely linked to the polypeptide, in
which serine and threonine are the major amino
acids, which makes the glycoproteins rather resistant
to proteinase digestion. In serum-type glycoproteins,
however, sugar-linking asparagine is rather sparsely
distributed in the polypeptide, which makes the
glycoproteins susceptible to proteinases. Thus, ex-
tensive digestion of these glycoproteins with pronase
produces glycopeptides of diﬀerent sizes that were
separated by gel ﬁltration on Sephadex G-50,
namely G-50I from mucin-type glycoproteins and
G-50II from serum-type glycoproteins, respectively.
G-50I is eluted from the column earlier than G-50II.
These glycopeptides will be dealt with in Sections II
and III.
Section II. Characterization of membrane
glycoproteins
We have been particularly interested in cell
surface glycoproteins because they determine cell
behaviour. Comparison of cancer versus normal cells
in humans is an attractive approach. Prior to this
approach, we investigated the cell membranes of rat
liver and hepatomas. Due to the limited space, the
results are summarized as follows.
1. All the subcellular membranes examined
contained certain amounts of sugar. Plasma
membranes contained more sialic acid than
intracellular membranes. No mucin-type glyco-
proteins are present in liver or regenerating liver
of rats.13)–15)
2. Plasma membranes of high purity were pre-
pared from hepatoma cells. The membranes
contained more than 30 protein components,
several of which were glycoproteins. A major
glycoprotein was isolated that contained about
40% sugar composed of both O-glycosidically
and N-glycosidically linked sugar units.16) The
structures of nine O-glycosidic sugar units
derived from the major glycoproteins were
determined. The smallest unit was N-acetyl-
galactosamine (GalNAc) and the largest one
was GlcNAc-containing hexasaccharide. Some
of them were novel sugar units.17)
3. The plasma membranes from hepatomas con-
tained proteoglycans. Heparan sulphate and
chondroitin sulphate were identiﬁed for AH 66
and AH 130, respectively, as their sugar
chains.18)
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monoclonal antibodies
Many sugar chain-directed monoclonal anti-
bodies are regarded as eﬀective agents for detecting
tumor markers.19) Using the LS 180 and SW 1116
cell lines, which were separated from human colo-
rectal cancer tissues and which were provided by
the Type Culture Collection, USA, we have tried
to establish hybridoma clones producing sugar-
directed monoclonal antibodies recognizing tumor
markers more eﬀectively. Unfortunately, we did not
have reliable human cancer cell lines in Japan at that
time.
Glycoproteins embedded in cell surface mem-
branes are often potent antigens. We adopted a
means of immunizing mice with whole cells that led
to the production of many antibodies directed to
antigenic molecules on the cell surface. However, it is
tedious to select hybridoma clones that produce
sugar-directed and cancer-associated antibodies from
among large numbers of hybridomas by means of
cell-binding assaying of the antibodies.19) We have
invented a new procedure for selecting hybridomas in
this regard.20)
(i) From LS 180 cells. The cell membranes of
LS 180 cells were prepared by treating the cells with a
buﬀer containing 1% Triton X-100. This treatment
does not result in membranes of high purity, but
assures the release of glycoproteins and glycolipids
from the cells. After the removal of lipids, the
remaining sample was exhaustively digested with
pronase to produce G-50I and G-50II. The reason
why we used glycopeptides for the detection of
antibodies instead of sugar chains released from
polypeptides is that some antibodies might recognize
not only sugar chains but also those attached to a
limited region of peptides.
To detect antibodies directed to G-50I, immuno-
assay plates were coated with these glycopeptides
with the aid of glutaraldehyde and polylysine. For
G-50II, the glycopeptides were acylated with palmitic
acid to increase the coating eﬃciency. Coating with
glycolipids was carried out using a conventional
procedure.
In the experiments involving LS 180 cells, the
culture ﬂuid produced by hybridomas in 12 out of
7X96 wells showed signiﬁcant binding to G-50I
and/or G-50II plates, and one of them showed
binding to only G-50I plates. Cloning of the hybri-
domas by the limited dilution method led to the
establishment of more than ten clones.20)
(ii) MLS 102 antibody. The epitopic structure
for one of the antibodies, designated as MLS 102, was
determined. MLS 102 reacted with a wide variety
of mucin-type glycoproteins, which included ovine
(OSM), bovine (BSM), and porsine (PSM) submax-
illary mucins.21) OSM exhibited exceedingly high
reactivity compared to other mucin-type glycopro-
teins, even more than that of G-50I prepared from
LS180 cells. The sugar units constituting OSM, BSM
and PSM had already been investigated to some
extent. In OSM, Sia,2→6GalNAc,→Ser/Thr in the
polypeptide chain had been identiﬁed as the main
structure of the sugar attachment motif. In BSM and
PSM, some longer sugar chains had been detected in
addition to the OSM disaccharide.
Further studies revealed that Sia,2→
6GalNAc(or Gal) was the complete antigen for
MLS 102 although its antigenic reactivity was only
one thousandth of that of OSM. Sialic acid and
Sia,2→3Gal were incomplete antigens, inhibiting
the antigen–antibody reaction only partially even
at very high concentrations. N-Glycolylsialic acid
and trisaccharides in which galactose is attached to
GalNAc of the antigenic disaccharide were com-
pletely inactive. The big diﬀerence in antigenic
activity between OSM and the released disaccharide
may be explained according to the immunologic
concept of avidity. This contrasts the aﬃnity
between a monovalent antigen and an antibody.22)
MLS 102 did not react with umbilical cord
tissue, amniotic ﬂuid, saliva, seminal ﬂuid, meconium
or human milk, but reacted with the mucosal
epithelium of the esophagus and stomach of humans.
The use of MLS 102 as a tumor marker antibody
awaits further investigation.
The antigens derived from LS 180 cells were
puriﬁed by immunoaﬃnity column chromatography.
Sugar chains were released from the puriﬁed antigens
by alkaline borohydride treatment. The sugar chains
of the MLS 102 antigen were composed of 0-linked
Sia,2→6GalNAc (56%) and 0-linked GalNAc (25%)
residues. Thus, the antigen apparently possesses an
OSM-like structure as shown in Fig. 2. An 0-linked
Sia,2→6GalNAc residue is not a speciﬁc sugar chain
in the cancer-associated antigen, being also found in
normal colonic mucins. However, the small amount
and probably limited distribution of the disaccharide
in the polypeptide chain are not enough for reaction
with MLS 102 type antibodies.
Other antibodies, MLS 103–MLS 105, did not
react with mono- and disaccharides, but reacted
with much longer sugar chains (Fig. 2). These
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normal mucosal epithelium. The diﬀerences in
size and structure of sugar chains between cancer-
associated and -unassociated antigens may support
the idea that the malignant transformation of cells
is accompanied by aberrant and incomplete glyco-
sylation.23),24)
(iii) MLS 128 (anti-Tn) antibody. The next
antibody we investigated was MLS 128, which was
assigned as an anti-Tn antibody based on its capacity
to agglutinate Tn erythrocytes. Tn antigen was
discovered in 1959 as an antigen on erythrocytes of
a patient with hemolytic anemia,25) and is regarded
as a tumor-associated antigen.26),27) Since then it
has been believed that GalNAc-Ser/Thr is included
in Tn antigen,28) but its exact epitopic structure is
unknown. Two anti-Tn monoclonal antibodies are
known. One is NCC-LU-35 which was raised against
human lung cancer cells,29) and the other is CA 3239,
which was raised against glycophorin A from Tn
erythrocytes.30) These antibodies and MLS 128
inhibited the reactions with Tn erythrocytes, G-50I
from LS 180 cells and OSM each other completely.
All the anti-Tn antibodies reacted with asialo G-50I
and asialo OSM to the same extent as with the
intact antigens. These ﬁndings suggest that all
known anti-Tn antibodies recognize the same epi-
tope. Digestion of asialo OSM with pronase reduced
the binding capacity of asialo OSM as to all the
anti-Tn antibodies.31) Digestion of asialo OSM with
trypsin, V8 protease and thermolysin, followed by
fractionation of the digests, led to the isolation of
a glycopeptide with strong immunoreactivity. The
glycopeptide had the sequence of Leu–Ser*–Thr*–
Thr*–Gln–Leu–Pro–Gly (asterisks indicate that a
GalNAc residue is linked).32)
Similar studies were carried out on glycophorin
A from human erythrocytes. We could use a
glycoprotease from Pasteurella haemolytica A1 that
is capable of hydrolyzing sialylated mucin-type
glycoproteins.33) On treatment of the glycoprotease
digest with sialidase and --galactosidase, Tn
antigenicity was induced since Sia,2→3Gal-1→
3(Sia,2→6)GalNAc-Ser/Thr is one of the major
sugar chains of glycophorin A. Fractionation of
the digest by HPLC led to the isolation of ﬁve
glycopeptides with potential Tn antigenicity, as
shown in Fig. 3. The reactivities of the three- and
four-consecutive-residue sequences of GalNAc-Ser/
Thr were equal.34)
We found that a major glycoprotein, leukosialin
(CD 43), of a T-lymphoid cell line, Jurkat, expresses
Tn antigen.35) On the basis of its amino acid
sequences and sugar structure,36),37) leukosialin seems
to contain seven cluster structures, each consisting of
three or four consecutive GalNAc-Ser/Thr residues.
gp120, a coat protein of human immunoreactive
virus, also expresses Tn antigen.38) Although the
antigenic site has not been determined, possible
consecutive sites to which GalNAc is bound could
be found in the deduced amino acid sequence.39)
These glycoproteins and Tn antigens all appear to
play signiﬁcant biological roles.
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Fig. 2. Proposed gross structures of the MLS 102 and MLS 103
antigens. Dark bands, nonglycosylated regions of the polypep-
tide chain. G, GalNAc. N, NeuAc. , any monosaccharide
constituting linear or branched oligosaccharide chains.
Leu-Ser-Thr-Thr-Glu-Val-Ala-Met-His-Thr-Ser-Thr-Ser-Ser-Ser-Val-Thr-Lys-Ser-Tyr-Ile Ser Gly
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Fig. 3. Structures and immunoreactivities of the glycopeptides
derived from glycophorin A. GPA, glycopeptides derived from
glycophorin A. The reactivity which was determined using 125I-
labeled protein A and is expressed relative to the clusters of three
consecutive GalNAc-Ser/Thr. • indicates O-glycosylation sites.
The sequence indicates from the N terminus to Ile-21 comprising
the MM and NN types of glycophorin.
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involving SW 1116 cells established 14 monoclonal
antibodies, designated as MSW 111–MSW 124.40)
They were classiﬁed into three types, Types A–C.
Twelve of the 14 antibodies were Type A ones that
reacted with G-501 and glycolipids, but did not react
with their asialo forms. All the A type antibodies
were found to recognize the same epitope since on the
binding of these antibodies to G-50I they inhibited
each other completely. The type B antibody, MSW
111, reacted with G-50I, asialo G-50I, G-50II and
glycolipids. The type C antibody, MSW 124, did not
react with GP-I, but did with GP-II and glycolipids.
The antibodies belonging to Types B and C were not
investigated further since they reacted with normal
tissues strongly.
(v) MSW 113 antibody. MSW 113, one of the
A Type antibodies was chosen for further studies
since the growth rate and antibody productivity of
the hybridoma producing this antibody were highest
among the hybridoma clones producing other A Type
antibodies.
Since MSW 113 reacted with both mucin-type
glycoproteins and glycolipids, the epitope should be
the sugar moiety of these glycoconjugates. Candidate
oligosaccharides with known structures were exam-
ined as to their reactivity with MSW 113, which
suggested that sialyl-Lea type sugar chains comprise
one group of epitopes.
Human colostrum is known to contain a number
of oligosaccharides and some of them carry determi-
nants for blood group antigens including Lea. This
background information prompted us to look for
epitopic oligosaccharide(s) in human colostrum.
From an immunoaﬃnity column containing MSW
113, immunoreactive oligosaccharides were obtained
in the eluate.41) By fractionating oligosaccharides
in the eluate on a column of TSK-GEL NH2,1 4
oligosaccharides could be isolated.42)
Determination of the structures of these oligo-
saccharides was performed by 1H-NMR and FAB-
MS. Most of the oligosaccharides recognized by MLS
113 had the sialyl-Lea structure, nine of them having
novel structures.43)–46) Some representative oligosac-
charides are shown in Fig. 4.
In addition, four oligosaccharides of known
structures, A–D, were identiﬁed.42) A was sialyl-
lacto-N-tetraose (CA 50), which is known as antigen
recognized by the C-50 antibody,42) and is a useful
tumor marker for pancreatic cancer. B was an
antigen for the FH 9 antibody and is frequently
detected in liver and pancreatic cancer.47) C was an
antigen for the FH 7 antibody.48) D was disialyl-
mono-fucosyl lacto-N-hexaose.49) It should be noted
that none of oligosaccharides A–D had the sialyl-Lea
structure, yet they reacted with MSW 113.42)
(vi) Comparison of MSW 113 with NS 19-9.
While many monoclonal antibodies recognizing
tumor antigens have been produced, antibodies
towards CEA and CA 19-9 are the most popular
and are utilized mainly for diagnosis of gastro-
intestinal cancer. CEA is a glycoprotein with anti-
genic sites residing in the polypeptide moiety. CA 19-
9 recognized by the NS 19-9 antibody is an oligosac-
charide, sialyl-Lea hexasaccharide, which is one of the
major antigenic oligosaccharides as to MSW 113. We
have compared the levels of antigens in sera of
various cancer patients using NS 19-9 and MSW 113.
In gastrointestinal cancer, these two antibodies
revealed abnormal levels of the antigens of nearly
the same extent. However, the patients with liver,
gall bladder and pancreatic cancer who appeared
normal on NS 19-9 screening showed distinctly
abnormal values with MLS 113. Furthermore,
immunostaining of stomach and pancreatic cancer
tissues gave more intensive images with MSW 113
than with NS 19-9.
Figure 4 shows the reactivities of MSW 113
and NS 19-9 with oligosaccharides having the sialyl-
Lea structure isolated from human colostrum. The
reactivities were determined as the inhibition of the
binding of these two antibodies to G-50I from SW
1116 cells. While the reactivities of all the oligosac-
charides were nearly the same for MSW 113, the
values were divergent for NS 19-9. Even with sialyl-
Lea hexasaccharide, the reactivity of NS 19-9 was
only about one-sixth of that of MSW 113. NS 19-9
seems to react poorly with branched oligosaccharides
such as Fractions 2–4, and with oligosaccharides
lacking the reducing terminal lactose structure such
as Fractions 5 and 6. The reactivities of oligosaccha-
rides A–D derived from colostrum with NS 19-9 were
very poor, being nearly unreactive, and a concen-
tration of more than 3 mM being required to detect
the reactivity. These results clearly indicate that
antibody MSW 113 reacts with not only sialyl-Lea
oligosaccharides but also non-Lea ones, while NS 19-9
is reactive only with sialyl-Lea oligosaccharides.
These diﬀerences between the two antibodies show
that MSW 113 should be more useful than NS 19-9 as
an antibody recognizing tumor markers.
To summarize the binding experiments, we
present an illustration of the epitope recognition by
MSW 113 and NS 19-9, in Fig. 5.
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proteins and oligosaccharides produced by can-
cer cells recognized by MSW 113. Western blot
analyses of the antigens recognized by MSW 113 that
appeared in culture medium of SW 1116 cells, and
sera from patients with pancreatic or stomach cancer
showed that the antigens are very large molecules
with molecular sizes in the range of 100–200KDa.
Oligosaccharides were released by alkaline boro-
hydride treatment from the cell lysates and culture
media of LS 180 and SW 1116 cells that had been
metabolically labeled with [3H] glucosamine. The
oligosaccharides were fractionated by aﬃnity chro-
113
19-9
NeuAcα2 3Galβ1 3GlcNAcβ1 3Galβ1
Fucα1
4
Fig. 5. Illustration of the epitope recognition of MSW 113 and
NS 19-9.
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Fig. 4. Reactivities with MSW 113 and NS 19-9 of the oligosaccharides with the sialyl-Lea structure in human milk. The reactivities were
determined as the inhibition of the binding of NSW 113 and NS 19-9 to G-50I derived from SW 1116 cells. Figures express the
amounts (µM) of inhibitors to give 50% inhibition.
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The amounts of the immunoreactive oligosaccharides
in the eluate from the immunoaﬃnity column,
expressed on the basis of radioactivity, were 20%,
10%, 7% and 4%, respectively, of the totals for SW
1116 cells, LS 180 cells, SW 1116 culture medium and
LS 180 culture medium, respectively. The immuno-
reactive oligosaccharides were submitted to gel
ﬁltration on Sephadex G-50. Surprisingly, the radio-
activity of all samples was distributed in an apparent
molecular weight range of 2,000 to 10,000.50) By
treating the oligosaccharides with endo---galacto-
sidase of Escherichia freundii,51) about 30% of the
radioactivity was released as oligosaccharides with
molecular weights of 1,000–1,500. These results
indicate that the oligo- or polysaccharides recognized
by MSW 113 from human colorectal cancer cells are
complex in structure, and that some of them contain
the poly-N-acetyllactosamine structure. There has
been a report in which the authors claimed that
many of the sialyl-Lea oligosaccharides on the
glycoproteins from SW 1116 culture medium are
extremely large and structurally complex N-linked
poly-N-acetyllactosamines.52) In our study, however,
the oligosaccharides recognized by MSW 113 were
found not to contain mannose, indicating that all the
oligosaccharides are O-linked sugar chains, as they
are in human seminal plasma and amniotic ﬂuid.53)
Summary
In this review, I have summarized the works
which I and my colleagues accomplished for a period
of about 50 years since 1953. Starting from the
establishment of the basic structures of glyco-
proteins, we have investigated the structural and
immunological properties of the sugar moieties of cell
membrane glycoproteins. Using a new procedure for
selecting hybridomas, monoclonal antibodies recog-
nizing the sugar moieties of cell membrane glyco-
proteins could readily be established. Some of these
antibodies seem to be eligible for the use in cancer
diagnosis.
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